Prospective Cohort Study of Disease and Outcomes in Cirrhosis

Launched by COPENHAGEN UNIVERSITY HOSPITAL, HVIDOVRE · Jun 4, 2020

Keywords

ClinConnect Summary

This clinical trial is looking to learn more about liver cirrhosis, a serious condition where the liver becomes damaged and scarred. Researchers want to understand how the disease develops, what factors might lead to early death or hospital visits, and how new tools can help monitor and treat the condition. To do this, they will be enrolling patients who have recently been diagnosed with cirrhosis, regardless of the cause.

To participate, individuals should be between the ages of 65 and 74 and have a medical evaluation that suggests cirrhosis, supported by blood tests and imaging studies like ultrasounds. Participants will need to provide written consent to join the study. Those who are unsure about their diagnosis or who have been diagnosed with liver cirrhosis through reliable tests will not be eligible. If you join the study, you can expect to contribute to important research that could improve care for others with this condition.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Clinical suspicion of cirrhosis supported by biochemistry and ultrasound or other imaging techniques.
• • Cirrhosis of any etiology
• • Informed written consent
• Exclusion Criteria:
• • People where the diagnosis of liver cirrhosis is questioned with reasonable doubt or the diagnosis of liver cirrhosis is disproved by histology or relevant imaging.
• • Withdrawal of informed consent or no informed consent.
• • Persons eligible for inclusion where the investigational program is delayed or not initiated within six months after the diagnosis of suspected cirrhosis.